Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Fresenius Medical Care (XETRA: FME; NYSE: FMS), a global leader in renal disease care, announced the divestment of select assets of its wholly owned Spectra Laboratories to Quest Diagnostics (NYSE: DGX). Under the agreement, Quest will acquire laboratory assets focused on renal-specific testing in the U.S. Additionally, Quest will provide comprehensive dialysis-related lab and water testing services to Fresenius Medical Care's clinics in the U.S.
This acquisition will allow Quest to enhance its portfolio with dialysis-related water testing capabilities. The deal is expected to bring operational efficiencies to Fresenius Medical Care and leverage Quest's national scale, reducing transportation times and speeding up results reporting. Financial terms were not disclosed, and the acquisition is expected to close in the second half of 2025, with service transitions completing by early 2026.
Fresenius Medical Care is in the second year of a three-year strategic turnaround plan, focusing on optimizing its portfolio by divesting non-core and dilutive assets. Chronic kidney disease affects approximately 35.5 million people in the U.S., with over 800,000 receiving dialysis. This transaction aligns with Fresenius Medical Care's strategy to concentrate on its core business of providing dialysis care.
Fresenius Medical Care (XETRA: FME; NYSE: FMS), un leader globale nella cura delle malattie renali, ha annunciato la dismissione di alcuni asset della sua controllata Spectra Laboratories a Quest Diagnostics (NYSE: DGX). In base all'accordo, Quest acquisirà asset di laboratorio focalizzati su test specifici per i reni negli Stati Uniti. Inoltre, Quest fornirà servizi completi di test di laboratorio e di acqua relativi alla dialisi alle cliniche di Fresenius Medical Care negli Stati Uniti.
Questa acquisizione permetterà a Quest di ampliare il suo portafoglio con capacità di test dell'acqua relative alla dialisi. Si prevede che l'accordo porti a efficienze operative per Fresenius Medical Care e sfrutti la scala nazionale di Quest, riducendo i tempi di trasporto e accelerando la segnalazione dei risultati. I termini finanziari non sono stati divulgati e si prevede che l'acquisizione si chiuda nella seconda metà del 2025, con le transizioni dei servizi completate entro l'inizio del 2026.
Fresenius Medical Care è nel secondo anno di un piano strategico di ristrutturazione triennale, focalizzandosi sull'ottimizzazione del suo portafoglio attraverso la dismissione di asset non core e diluitivi. La malattia renale cronica colpisce circa 35,5 milioni di persone negli Stati Uniti, con oltre 800.000 che ricevono dialisi. Questa transazione è in linea con la strategia di Fresenius Medical Care di concentrarsi sul suo core business di fornitura di assistenza per la dialisi.
Fresenius Medical Care (XETRA: FME; NYSE: FMS), un líder global en el cuidado de enfermedades renales, anunció la desinversión de algunos activos de su filial Spectra Laboratories a Quest Diagnostics (NYSE: DGX). Según el acuerdo, Quest adquirirá activos de laboratorio enfocados en pruebas específicas para riñones en los EE. UU. Además, Quest proporcionará servicios integrales de pruebas de laboratorio y de agua relacionados con la diálisis a las clínicas de Fresenius Medical Care en los EE. UU.
Esta adquisición permitirá a Quest mejorar su cartera con capacidades de pruebas de agua relacionadas con la diálisis. Se espera que el acuerdo genere eficiencias operativas para Fresenius Medical Care y aproveche la escala nacional de Quest, reduciendo los tiempos de transporte y acelerando la entrega de resultados. No se divulgaron los términos financieros, y se espera que la adquisición se cierre en la segunda mitad de 2025, con las transiciones de servicio completadas a principios de 2026.
Fresenius Medical Care se encuentra en el segundo año de un plan estratégico de reestructuración de tres años, centrado en optimizar su cartera mediante la desinversión de activos no centrales y dilutivos. La enfermedad renal crónica afecta a aproximadamente 35,5 millones de personas en los EE. UU., con más de 800,000 recibiendo diálisis. Esta transacción está alineada con la estrategia de Fresenius Medical Care de concentrarse en su negocio principal de atención a la diálisis.
프레제니우스 메디컬 케어 (XETRA: FME; NYSE: FMS)는 신장 질환 치료의 글로벌 리더로서, 전액 출자한 스펙트라 연구소의 일부 자산을 퀘스트 진단 (NYSE: DGX)에게 매각한다고 발표했습니다. 이 계약에 따라, 퀘스트는 미국 내 신장 전문 검사에 중점을 둔 실험실 자산을 인수합니다. 또한, 퀘스트는 미국 내 프레제니우스 메디컬 케어의 클리닉에 대해 종합적인 투석 관련 실험실 및 수질 검사 서비스를 제공합니다.
이번 인수는 퀘스트가 투석 관련 수질 검사 능력을 통해 포트폴리오를 강화할 수 있게 해줍니다. 이 거래는 프레제니우스 메디컬 케어에 운영 효율성을 가져오고 퀘스트의 국가적 규모를 활용하여 운송 시간을 줄이고 결과 보고 속도를 높일 것으로 예상됩니다. 재무 조건은 공개되지 않았으며, 인수는 2025년 하반기에 완료될 것으로 예상되며 서비스 전환은 2026년 초까지 완료될 예정입니다.
프레제니우스 메디컬 케어는 비핵심 및 희석 자산을 매각하여 포트폴리오를 최적화하는 데 집중하고 있는 3년 전략적 전환 계획의 두 번째 해에 있습니다. 만성 신장 질환은 미국에서 약 3,550만 명에게 영향을 미치며, 80만 명 이상이 투석을 받고 있습니다. 이번 거래는 프레제니우스 메디컬 케어가 투석 치료라는 핵심 사업에 집중하는 전략과 일치합니다.
Fresenius Medical Care (XETRA: FME; NYSE: FMS), un leader mondial dans le domaine des soins des maladies rénales, a annoncé la cession de certains actifs de sa filiale à 100 % Spectra Laboratories à Quest Diagnostics (NYSE: DGX). Selon l'accord, Quest acquerra des actifs de laboratoire axés sur les tests spécifiques aux reins aux États-Unis. De plus, Quest fournira des services complets de tests de laboratoire et d'analyse de l'eau liés à la dialyse aux cliniques de Fresenius Medical Care aux États-Unis.
Cette acquisition permettra à Quest d'enrichir son portefeuille avec des capacités d'analyse de l'eau liées à la dialyse. Il est prévu que cet accord apporte des gains d'efficacité opérationnelle à Fresenius Medical Care et tire parti de l'échelle nationale de Quest, réduisant ainsi les temps de transport et accélérant la communication des résultats. Les conditions financières n'ont pas été divulguées, et l'acquisition devrait être finalisée au second semestre 2025, avec des transitions de services achevées début 2026.
Fresenius Medical Care est dans la deuxième année d'un plan stratégique de redressement de trois ans, axé sur l'optimisation de son portefeuille par la cession d'actifs non essentiels et dilutifs. La maladie rénale chronique touche environ 35,5 millions de personnes aux États-Unis, dont plus de 800 000 reçoivent une dialyse. Cette transaction s'inscrit dans la stratégie de Fresenius Medical Care de se concentrer sur son cœur de métier dans les soins de dialyse.
Fresenius Medical Care (XETRA: FME; NYSE: FMS), ein globaler Marktführer in der Nierenkrankheitenversorgung, gab die Veräußerung ausgewählter Vermögenswerte seiner hundertprozentigen Tochtergesellschaft Spectra Laboratories an Quest Diagnostics (NYSE: DGX) bekannt. Im Rahmen der Vereinbarung wird Quest Laborvermögen erwerben, das sich auf nieren-spezifische Tests in den USA konzentriert. Darüber hinaus wird Quest umfassende labortechnische und wasseranalytische Dienstleistungen im Zusammenhang mit der Dialyse für die Kliniken von Fresenius Medical Care in den USA bereitstellen.
Diese Akquisition wird es Quest ermöglichen, sein Portfolio mit Fähigkeiten zur Wasseranalyse im Zusammenhang mit der Dialyse zu erweitern. Es wird erwartet, dass der Deal betriebliche Effizienzen für Fresenius Medical Care mit sich bringt und die nationale Reichweite von Quest nutzt, um Transportzeiten zu reduzieren und die Ergebnisberichterstattung zu beschleunigen. Finanzielle Einzelheiten wurden nicht bekannt gegeben, und die Akquisition wird voraussichtlich in der zweiten Hälfte des Jahres 2025 abgeschlossen, wobei die Übergänge der Dienstleistungen bis Anfang 2026 abgeschlossen sein sollen.
Fresenius Medical Care befindet sich im zweiten Jahr eines dreijährigen strategischen Umstrukturierungsplans, der darauf abzielt, sein Portfolio durch die Veräußerung von nicht zum Kerngeschäft gehörenden und verwässernden Vermögenswerten zu optimieren. Chronische Nierenerkrankungen betreffen etwa 35,5 Millionen Menschen in den USA, wobei über 800.000 Dialyse erhalten. Diese Transaktion steht im Einklang mit der Strategie von Fresenius Medical Care, sich auf ihr Kerngeschäft der Dialyseversorgung zu konzentrieren.
- Divestment of non-core assets aligns with Fresenius Medical Care's strategic turnaround plan.
- Expected operational efficiencies and enhanced patient experiences through Quest's diagnostic expertise.
- Quest's national scale to reduce transportation times and speed up results reporting.
- Quest adds dialysis-related water testing capabilities to its portfolio.
- Financial terms of the acquisition were not disclosed, creating uncertainty for investors.
Insights
This strategic divestment marks a pivotal shift in Fresenius Medical Care's business model, representing a sophisticated approach to capital allocation and operational optimization. The transaction accomplishes several key objectives:
- Operational Excellence: By leveraging Quest's extensive laboratory network, FME can reduce testing turnaround times and transportation costs across its 3,732 dialysis clinics serving approximately 308,000 patients.
- Market Positioning: This move allows FME to focus on its core competency in dialysis care while benefiting from Quest's expertise in laboratory diagnostics. With
14% of the U.S. population affected by chronic kidney disease, this partnership enhances service delivery to a significant patient base. - Financial Optimization: The deal structure suggests a potential reduction in capital expenditure requirements and operating costs, while maintaining service quality. Quest's ability to utilize its facilities during lower-volume periods indicates significant efficiency gains.
The timing is particularly strategic, coinciding with the second year completion of FME's three-year turnaround plan. This transaction could accelerate FME's transformation by streamlining operations and reducing non-core asset exposure. Quest's extensive reach, serving one-third of adult Americans annually, ensures robust infrastructure for handling FME's diagnostic needs.
The arrangement's structure as both an asset sale and service agreement creates a sustainable long-term partnership model, potentially reducing operational complexity while maintaining service quality. This could translate into improved EBITDA margins through reduced overhead costs and more efficient resource allocation.
- Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in
the United States
BAD HOMBURG,
In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in
By acquiring select laboratory assets from FME, Quest will add dialysis-related water testing, a new capability, to Quest's comprehensive portfolio. The arrangement will enable FME to gain operational efficiencies and allow FME and other providers and patients at dialysis clinics to benefit from Quest's clinical leadership and diagnostic innovation in chronic kidney disease and transplantation services. It will also leverage Quest's national scale, as multiple Quest laboratories spread across the
Financial terms were not disclosed. The acquisition is expected to close in the second half of 2025, pending customary state regulatory reviews. The transition of services is expected to be complete by early 2026.
"This transaction is part of our comprehensive portfolio optimization strategy to drive operational efficiencies and will provide enhanced experiences for patients and our clinical employees by integrating Quest Diagnostic's industry-leading expertise in laboratory medicine into our dialysis centers. This agreement is a step forward to allow us to remain focused on our core business of providing world-class dialysis care to every patient, every day," said Helen Giza, Chief Executive Officer of Fresenius Medical Care. "Much like Fresenius Medical Care, Quest Diagnostics is passionate about creating a healthier future for patients. These shared values, along with Quest's proven track record for quality care and service, make us confident that they are the right company to continue to deliver a high-quality experience to our patients, physician partners, and clinical staff."
"Our relationship with Fresenius Medical Care will extend our industry-leading test portfolio in chronic kidney disease, one of the nation's most prevalent chronic diseases, to include dialysis-related laboratory and water testing," said Jim Davis, Chairman, CEO and President, Quest Diagnostics. "It will also optimize Quest's national scale to bring high-quality laboratory services closer to FME's dialysis clinics and the patients under their care across
Fresenius Medical Care recently successfully finished year two of a three-year strategic turnaround and transformation plan. Focusing on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care is continuing to execute against its portfolio optimization plan to divest non-core and dilutive assets.
Chronic kidney disease affects about 35.5 million people, or
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,732 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 308,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at www.freseniusmedicalcare.com.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
FME Media contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
FME Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
Quest Media contact
Jen Petrella
T +1 973-520-2800
mediacontact@QuestDiagnostics.com
Quest Contact for analysts and investors
Shawn Bevec
T +1 973-520-2900
shawn.c.bevec@questdiagnostics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-announces-divestment-of-select-laboratory-assets-to-quest-diagnostics-302383348.html
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What does the FMS divestment to Quest Diagnostics involve?
How will the FMS divestment to Quest impact operational efficiencies?
When is the FMS and Quest Diagnostics acquisition expected to close?
What new capability will Quest add through the FMS divestment?
How does the FMS divestment align with its strategic goals?
How many people in the U.S. are affected by chronic kidney disease?
What is the significance of Quest Diagnostics providing lab services to FMS clinics?
